BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 35748231)

  • 1. [A Case Report of a Patient with Metastatic Adrenocortical Carcinoma who Received the Combination Etoposide, Doxorubicin, Cisplatin, and Mitotane Therapy and Achieved Remission].
    Ueda S; Nakane K; Namiki S; Takeuchi Y; Kawase M; Takeuchi S; Kawase K; Nakai C; Kato D; Takai M; Iinuma K; Tsuchiya T; Miyazaki T; Koie T
    Hinyokika Kiyo; 2022 May; 68(5):139-143. PubMed ID: 35748231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer.
    Berruti A; Terzolo M; Pia A; Angeli A; Dogliotti L
    Cancer; 1998 Nov; 83(10):2194-200. PubMed ID: 9827725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A Case of Adrenocortical Carcinoma Successfully Treated with Multimodal Therapy].
    Bando S; Ishii G; Yamada H; Kimura T; Furuta N; Egawa S
    Hinyokika Kiyo; 2016 Jan; 62(1):15-9. PubMed ID: 26932330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Three Cases of Advanced or Recurrent Adrenocortical Carcinoma Patients Treated with Etoposide, Doxorubicin and Cisplatin plus Mitotane].
    Sasaki S
    Gan To Kagaku Ryoho; 2018 Jan; 45(1):67-70. PubMed ID: 29362311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma: mitotane monitoring and tumor regression.
    Zancanella P; Pianovski MA; Oliveira BH; Ferman S; Piovezan GC; Lichtvan LL; Voss SZ; Stinghen ST; Callefe LG; Parise GA; Santana MH; Figueiredo BC
    J Pediatr Hematol Oncol; 2006 Aug; 28(8):513-24. PubMed ID: 16912591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
    Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T
    Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A Case of Aldosterone-Producing Adrenocortical Carcinoma].
    Oshiro H; Shimizu Y; Nakayasu R; Utsunomiya N; Son C; Tsuji K; Asai S; Katsushima H; Ishihara M; Hashimoto K; Kanamaru S
    Hinyokika Kiyo; 2023 May; 69(5):131-135. PubMed ID: 37312493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitotane With or Without Cisplatin and Etoposide for Patients with a High Risk of Recurrence in Stages 1-3 Adrenocortical Cancer After Surgery.
    Sarvestani AL; Gregory SN; Teke ME; Terzolo M; Berruti A; Hernandez JM; Habra MA
    Ann Surg Oncol; 2023 Feb; 30(2):680-682. PubMed ID: 36305989
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of EDP-M on survival of patients with metastatic adrenocortical carcinoma: A population-based study.
    Debets P; Dreijerink KMA; Engelsman A; Dahele M; Haak HR; Steenaard RV; Kapiteijn E; Corssmit E; Menke-van der Houven van Oordt CW
    Eur J Cancer; 2024 Jan; 196():113424. PubMed ID: 37977106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adrenocortical Carcinoma: Role of Adjuvant and Neoadjuvant Therapy.
    Kenney L; Hughes M
    Surg Oncol Clin N Am; 2023 Apr; 32(2):279-287. PubMed ID: 36925185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study.
    Williamson SK; Lew D; Miller GJ; Balcerzak SP; Baker LH; Crawford ED
    Cancer; 2000 Mar; 88(5):1159-65. PubMed ID: 10699907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical management and outcomes associated with etoposide, doxorubicin, and cisplatin plus mitotane treatment in metastatic adrenocortical carcinoma: a single institute experience.
    Uchihara M; Tanioka M; Kojima Y; Nishikawa T; Sudo K; Shimoi T; Noguchi E; Maeshima AM; Yonemori K
    Int J Clin Oncol; 2021 Dec; 26(12):2275-2281. PubMed ID: 34468885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination chemotherapy in advanced adrenocortical carcinoma.
    Fassnacht M; Terzolo M; Allolio B; Baudin E; Haak H; Berruti A; Welin S; Schade-Brittinger C; Lacroix A; Jarzab B; Sorbye H; Torpy DJ; Stepan V; Schteingart DE; Arlt W; Kroiss M; Leboulleux S; Sperone P; Sundin A; Hermsen I; Hahner S; Willenberg HS; Tabarin A; Quinkler M; de la Fouchardière C; Schlumberger M; Mantero F; Weismann D; Beuschlein F; Gelderblom H; Wilmink H; Sender M; Edgerly M; Kenn W; Fojo T; Müller HH; Skogseid B;
    N Engl J Med; 2012 Jun; 366(23):2189-97. PubMed ID: 22551107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adrenocortical carcinoma.
    van Ditzhuijsen CI; van de Weijer R; Haak HR
    Neth J Med; 2007 Feb; 65(2):55-60. PubMed ID: 17379929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Favorable response of metastatic adrenocortical carcinoma to etoposide, adriamycin and cisplatin (EAP) chemotherapy. Report of two cases.
    Berruti A; Terzolo M; Paccotti P; Veglio F; Pia A; Dogliotti L; Angeli A
    Tumori; 1992 Oct; 78(5):345-8. PubMed ID: 1494808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncocytic adrenocortical carcinoma.
    Tanaka K; Kumano Y; Kanomata N; Takeda M; Hara I; Fujisawa M; Kawabata G; Kamidono S
    Urology; 2004 Aug; 64(2):376-7. PubMed ID: 15302503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group.
    Postlewait LM; Ethun CG; Tran TB; Prescott JD; Pawlik TM; Wang TS; Glenn J; Hatzaras I; Shenoy R; Phay JE; Keplinger K; Fields RC; Jin LX; Weber SM; Salem A; Sicklick JK; Gad S; Yopp AC; Mansour JC; Duh QY; Seiser N; Solorzano CC; Kiernan CM; Votanopoulos KI; Levine EA; Staley CA; Poultsides GA; Maithel SK
    J Am Coll Surg; 2016 Apr; 222(4):480-90. PubMed ID: 26775162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model.
    Hantel C; Jung S; Mussack T; Reincke M; Beuschlein F
    Endocr Relat Cancer; 2014 Jun; 21(3):383-94. PubMed ID: 24532475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxic treatment of adrenocortical carcinoma.
    Ahlman H; Khorram-Manesh A; Jansson S; Wängberg B; Nilsson O; Jacobsson CE; Lindstedt S
    World J Surg; 2001 Jul; 25(7):927-33. PubMed ID: 11572034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Diagnosis and treatment for adrenocortical carcinoma].
    Iihara M; Obara T
    Gan To Kagaku Ryoho; 2004 Mar; 31(3):342-5. PubMed ID: 15045937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.